Trial Profile

Phase II Study of Alisertib as a Single Agent in Recurrent and Refractory Central Nervous System Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alisertib (Primary) ; Carboplatin; Cisplatin; Cyclophosphamide; Etoposide; Methotrexate; Pegfilgrastim; Topotecan; Vincristine
Indications Rhabdoid tumour; Teratoma
Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Acronyms SJATRT

01 Sep 2026 Actual primary completion date changed from 1 Sep 2025 to 30 Sep 2025.
27 Feb 2023 Planned End Date changed from 1 May 2027 to 1 Sep 2027.
27 Feb 2023 Planned primary completion date changed from 1 May 2025 to 1 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com